COURAGE THERAPEUTICS INC

Newton, MA · CIK 0002069873 · Biotech · Private

Small molecule therapeutics targeting MC4R and MC3R receptors for metabolic disorders

couragetx.com →
Grants
$4.3M
7 awards
Sector median: 1
Raised
$4.5M
1 Form D · May 2025
17 months since last filing
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss$244,905
Federal grantDepartment of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss$244,905
Federal grantDepartment of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa$250,538
Federal grantDepartment of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa$250,538
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency$806,879
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency$1,669,553
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency$862,674
Private capital raisedForm D · SEC$4,510,963
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1870Jennerex, Inc.—$5.4M
1871AKTTYVA THERAPEUTICS, INC.——
1872Oncolix, Inc.—$8.9M
1873COURAGE THERAPEUTICS INC—$4.5M
1874Factor Holdings LLC—$25K
1875TearSolutions, Inc.—$36M
1876Optimvia, LLC—$75K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Isaac BarchasDirector
  • Roger ConeDirector
  • Daniel HousmanDirector · Executive Officer
  • Bruce LeutcherDirector

Patents

USPTO · 0 granted of 7
  • MC4R Agonist Peptidesapplication
  • MC3R Agonist Peptidesapplication
  • Anorexia-sensitizing Agentsapplication
  • MC3R Agonist Peptidesapplication
  • MC3R Antagonist Or Partial Agonist Peptidesapplication
  • MC3R Agonist Peptidesapplication
  • Anorexia-sensitizing Agentsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.